MARKET

UPB

UPB

UpStream Bio Inc.
NASDAQ
8.67
-1.12
-11.41%
Opening 12:43 03/27 EDT
OPEN
8.74
PREV CLOSE
9.79
HIGH
9.14
LOW
8.10
VOLUME
365.25K
TURNOVER
--
52 WEEK HIGH
33.68
52 WEEK LOW
5.14
MARKET CAP
468.65M
P/E (TTM)
-3.7672
1D
5D
1M
3M
1Y
5Y
1D
Midday Fly By: Carnival cuts forecast on fuel cost, Novartis to buy Excellergy
TipRanks · 3h ago
Upstream Bio Cut to In-Line From Outperform by Evercore ISI Group
Dow Jones · 4h ago
Upstream Bio Price Target Cut to $15.00/Share From $40.00 by Evercore ISI Group
Dow Jones · 4h ago
Evercore ISI Group Downgrades Upstream Bio to In-Line, Lowers Price Target to $15
Benzinga · 4h ago
Wix downgraded, TripAdvisor upgraded: Wall Street’s top analyst calls
TipRanks · 5h ago
Zenas Biopharma, Daqo New Energy And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Benzinga · 7h ago
Upstream Bio downgraded to In Line from Outperform at Evercore ISI
TipRanks · 8h ago
Upstream Bio Launches $150 Million At-The-Market Program
TipRanks · 21h ago
More
About UPB
Upstream Bio, Inc. is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist in clinical development, that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. It has advanced this highly potent monoclonal antibody into separate phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, commonly referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin.

Webull offers UpStream Bio Inc. stock information, including NASDAQ: UPB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, UPB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading UPB stock methods without spending real money on the virtual paper trading platform.